

> AORTIC STENOSIS (AS)


# VALVULAR HEART DISEASE

### AORTIC STENOSIS (AS)

### Etiology

• **Calcific:** predominant cause in 病人 >70 y; risk factors include HTN, ↑ chol., ESRD

• **Congenital** (ie, bicuspid AoV with premature calcification): cause in 50% of 病人 <70 y

• **Rheumatic heart disease** (AS usually accompanied by AR and MV disease)

• AS mimickers: subvalvular (HCMP, subAo membrane) or supravalvular stenosis

### 臨床表現 (usually indicates AVA <1 cm2 or concomitant CAD)

• **Angina:** ↑ O2 demand (hypertrophy) + ↓ O2 supply (↓ cor perfusion pressure) ± CAD

• **Syncope** (_exertional_): peripheral vasodil. with fixed CO → ↓ MAP → ↓ cerebral perfusion

• **Heart failure:** outflow obstruct + diastolic dysfxn → pulm. edema, esp. if ↑ HR/AF (↓ LV fill.)

• Acquired vWF disease (~20% of sev. AS): destruction of vWF; GI angiodysplasia

• Natural hx: usually slowly progressive (AVA ↓ ~0.1 cm2/y, but varies; _Circ_ 1997;95:2262), until 症狀 develop; mean survival based on 症狀: angina = 5 y; syncope = 3 y; CHF = 2 y

### Physical exam

• **Midsystolic crescendo-decrescendo** murmur at **RUSB**, harsh, high-pitched, radiates to carotids, apex (holosystolic = Gallavardin effect), ↑ with passive leg raise, ↓ with standing & Valsalva. Dynamic outflow obstruction (HCM) is the reverse.

• Ejection click after S1 sometimes heard with _bicuspid_ AoV

• Signs of severity: _late-peaking_ murmur, paradoxically split S2 or inaudible A2, small and delayed carotid pulse (“_pulsus parvus et tardus_”), LV heave, ⊕ S4 (occasionally palpable)

![](https://i.imgur.com/RI2UdSI.jpg)

_Pathophys Heart Dis_., 6th ed., 2015, for this et al.

### Diagnostic studies

• ECG: may see LVH, LAE, LBBB, AF (in late disease)

• CXR: cardiomegaly, AoV calcification, poststenotic dilation of ascending Ao, pulmonary congestion

• **Echo:** valve morphology, jet velocity, estim pressure gradient (∇) & calculate AVA, LVEF

• **Cardiac cath:** usually to _排除 CAD_ (in ~1/2 of calcific AS); for hemodyn. if disparity between exam & echo: ✔ pressure gradient (∇) across AoV, calc AVA (underestim. if mod/sev AR)

• **Dobutamine challenge** (echo or cath): if low EF and mean ∇ <40, use to differentiate:

_Afterload mismatch:_ 20% ↑ SV & ∇, no ∆ AVA (implies contractile reserve, ↑ EF post-AVR)

_Pseudostenosis:_ 20% ↑ SV, no ∆ in ∇, ↑ AVA (implies low AVA _artifact_ of LV dysfxn)

_Limited contractile reserve:_ no ∆ SV, ∇ or AVA (implies EF prob. will not improve with AVR)

![](https://i.imgur.com/JrAP2ye.jpg)

aAVA indexed to BSA <0.6 cm2/m2 also severe; bDSE → max jet vel ≥4 & AVA ≤1.0; csmall LV with ↓ stroke vol.

### 治療 (_Circ_ 2014;129:e521; _Lancet_ 2016;387:1312; _JACC_ 2017; 69:1313)

• Based on _symptoms:_ once they develop, AVR needed.

• **AVR:** indicated in **症狀** (stage D1); ** 無症狀 severe** + **EF** <**50%** (stage C2); or severe (stage C1) _and_ undergoing other cardiac surgery.

Reasonable if:

###  無症狀 severe (stage C1) _but_ either **症狀 or** ↓ **BP with exercise** (can _carefully_ exercise  無症狀 AS to uncover 症狀; do _not_ exercise 症狀 AS) or **very severe**

### 症狀 severe with low flow/∇ with low EF & response to dobuta (stage D2) or normal EF but AS felt to be cause of 症狀 (stage D3)

 無症狀 moderate AS (stage B) _and_ undergoing cardiac surgery

• Transcatheter AoV replacement (TAVR, see below) attractive alternative to surgery

• Medical (if not AVR candidate or to temporize): careful diuresis prn, control HTN, maintain SR; digoxin if ↓ EF & HF or if AF; _avoid_ venodilators (nitrates) & ⊖ inotropes (βB/CCB) if severe AS; avoid vigorous physical exertion once AS mod–severe;

? nitroprusside (w/ PAC) in HF with sev. AS, ↓ EF/CO, & HTN (_Circ_ 2013;128:1349)

• IABP: stabilization, bridge to surgery

• Balloon valvotomy: ↑ AVA, _but_ risk of stroke/AR & restenosis; ∴ bridge to AVR or palliation

### TAVR (transcatheter AoV replacement) (_JACC_ 2017;135:e1159)

• Valves: balloon-expandable or self-expanding. Most commonly deployed retrograde via perc. transfemoral access (best outcomes); also retrograde via axillary art. or ascend. Ao (via small sternotomy & aortotomy). Alternatively, antegrade transapical via small thoracotomy & LV puncture (if narrow iliofemoral artery or calcified Ao).

• Peri- & postprocedural complic.: low CO; annular rupture or coronary occlusion (both rare); stroke; local vascular; paravalvular leaks; CHB (? higher with self-expanding valve).

• Post op: lifelong ASA 75–100 mg + clopidogrel 3–6 mo

• Outcomes with TAVR. In _nonoperative 病人_ (ie, vs. med Rx): 44% ↓ mortality but still ~20% annual mortality in TAVR group (_NEJM_ 2012;366:1696; _JACC_ 2014;63:1972).

_High-risk 病人_ (STS predicted 30d surg. mort. >8%) vs. surgical AVR (SAVR): ≈ mortality & ↑ early risk of stroke with balloon-expand.; 20–30% ↓ in death or stroke with self-expand. (_Lancet_ 2015;385:2477; _JACC_ 2016;67:2565)

_Medium-risk 病人_ (predicted 30d-mort. ~4–8%): ≈ death/stroke (? ↓ with balloon-expandable via transfemoral) (_NEJM_ 2016;374:1609 & 2017;376:1321)

_Low-risk 病人_ (predicted 30d-mort. <4%): ↓ death or stroke (_NEJM_ 2019;380:1695 & 1706)

TAVR with ↑ vasc. complic. but ↓ bleeding, AKI, AF; need for PPM in ~25% with self-expand.

Mod/severe paravalvular AI in 5–10% at 2 y, ~14% at 5 y (may be lower in lower risk 病人). Repositionable valve has rate <1% at 1 y, but ~40% rate of PPM (_JAMA_ 2018;319:27).

### AORTIC REGURGITATION (AR)

### Etiology (_Circ_ 2006;114:422)

• **Valve disease** (43%): **rheumatic heart disease** (usually mixed AS/AR + MV disease); **bicuspid AoV** (natural hx: 1/3 → normal, 1/3 → AS, 1/6 → AR, 1/6 → endocarditis → AR); **infective endocarditis;** valvulitis (RA, SLE, certain anorectics & serotonergics, XRT)

• **Root disease** (57%): **HTN**, aortic aneurysm/dissection, annuloaortic ectasia (ie, Marfan),

### aortic inflammation (GCA, Takayasu’s, ankylosing spond., reactive arthritis, syphilis)

### 臨床表現

• Acute: sudden ↓ forward SV and ↑ LVEDP (noncompliant ventricle) → pulmonary edema

± hypotension and cardiogenic shock

• Chronic: clinically silent while LV dilates (to ↑ compliance to keep LVEDP low) more than it hypertrophies → chronic volume overload → LV decompensation → CHF

• Natural hx: _variable_ progression (unlike AS, can be fast or slow); once decompensation begins, prognosis poor without AVR (mortality ~10%/y)

![](https://i.imgur.com/uu3WMcB.jpg)

### Physical exam

• **Early diastolic decrescendo murmur at LUSB** (RUSB if dilated Ao root); ↑ with sitting forward, expir, handgrip; severity of AR ∝ duration of murmur (except in acute and severe late); _Austin Flint murmur:_ mid-to-late diastolic rumble at apex (AR jet interfering with mitral inflow)

• **Wide pulse pressure** due to ↑ stroke volume, hyper-dynamic pulse; pulse pressure narrows in late AR with ↓ LV fxn; bisferiens (twice-beating) arterial pulse

• PMI diffuse and laterally displaced; soft S1 (early closure of MV); ± S3 (≠ ↓ EF but rather just volume overload in AR)

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p><b>Classic Eponymous Signs in Chronic AR</b> (<span><i>South Med J</i> 1981;74:459</span>)</p></td></tr><tr><td><p><b>Sign</b></p></td><td><p><b>Description</b></p></td></tr><tr><td><p>Corrigan’s pulse</p></td><td><p>“water hammer” pulse (ie, rapid rise/fall or distention/collapse)</p></td></tr><tr><td><p>Hill’s sign</p></td><td><p>(popliteal SBP – brachial SBP) &gt;60 mmHg</p></td></tr><tr><td><p>Duroziez’s sign</p></td><td><p>to-and-fro murmur heard over femoral artery with light compression</p></td></tr><tr><td><p>Pistol shot sounds</p></td><td><p>pistol shot sound heard over femoral artery</p></td></tr><tr><td><p>Traube’s sound</p></td><td><p>double sound heard over femoral artery when compressed distally</p></td></tr><tr><td><p>de Musset’s sign</p></td><td><p>head-bobbing with each heartbeat (low Se)</p></td></tr><tr><td><p>Müller’s sign</p></td><td><p>systolic pulsations of the uvula</p></td></tr><tr><td><p>Quincke’s pulses</p></td><td><p>subungual capillary pulsations (low Sp)</p></td></tr></tbody></table>

### Diagnostic studies

• ECG: can see LVH, LAD, 異常 repol; CXR: cardiomegaly ± ascending Ao dilatation

• **Echo:** severity of AR (severe = regurg jet width ≥65% LVOT, regurg fraction ≥50%, effective regurg orifice ≥0.3 cm2, holodiastolic flow reversal in descend. Ao; moderate = jet width 25–64%, regurg fraction 30–49%, regurg orifice 0.1–0.29 cm2); LV size & fxn

### 治療 (_Circ_ 2014;129:e521; _Lancet_ 2016;387:1312)

• Acute decompensation (consider endocarditis as possible acute precipitant):

_surgery_ usually urgently needed for acute severe AR, which is poorly tolerated by LV

IV afterload reduction (nitroprusside) and inotropic support (dobutamine)

± chronotropic support (↑ HR → ↓ diastole → ↓ time for regurgitation)

pure vasoconstrictors and IABP contraindicated

• In chronic AR, management decisions based on _LV size and fxn_ (and before 症狀 occur)

• **Surgery** (AVR, replacement or repair if possible):

### Severe and **症狀** (if equivocal, consider stress test)

###  無症狀 _and_ either **EF** ≤**50%** or **LV dilation** \[LVESD >50 mm or LVESDi (indexed to BSA) ≥20 or 25 mm/m2 (_JACC_ 2019;73:1741)\] or undergoing cardiac surg

• Transcatheter AoV replacement (TAVR) being explored (_JACC_ 2013;61:1577 & 2017;70:2752)

• Medical therapy: **vasodilators** (nifedipine, ACEI/ARB, hydralazine) if severe AR with 症狀 or LV dysfxn & not operative candidate or to improve hemodynamics before AVR; no clear benefit in  無症狀 severe AR with mild LV dilation & 正常 LV fxn (_NEJM_ 2005;353:1342)

### MITRAL REGURGITATION (MR)

### Etiology (_Lancet_ 2009;373:1382; _NEJM_ 2010;363:156)

• **Primary** (degeneration of valve apparatus)

_Leaflet 異常:_ myxomatous (MVP), endocarditis, calcific RHD, valvulitis (collagen-vascular disease), congenital, anorectic drugs (phen-fen), XRT

_Chordae tendineae_ rupture: myxomatous, endocarditis, spontaneous, trauma

_Papillary muscle dysfxn_ b/c of ischemia or _rupture_ during MI \[usu. posteromedial papillary m. (supplied predominantly by PDA) vs. anterolateral (suppl. by diags & OMs)\]

• **Secondary (functional):** inferoapical papillary muscle displacement due to ischemic LV remodeling or DCM; HCM (_JACC_ 2015;65:1231)

### 臨床表現

• Acute: **pulmonary edema**, hypotension, cardiogenic shock (_NEJM_ 2004;351:1627)

• Chronic: typically  無症狀 for yrs, then as LV fails → progressive DOE, fatigue, AF, PHT

• Prognosis: 5-y survival with medical therapy is 80% if  無症狀, but only 45% if 症狀

### Physical exam

• **High-pitched, blowing, holosystolic murmur at apex;** radiates to axilla; ± thrill; ↑ with handgrip (Se 68%, Sp 92%),

↓ with Valsalva (Se 93%) (_NEJM_ 1988;318:1572)

ant. leaflet 異常 → post. jet heard at spine

post. leaflet 異常 → ant. jet heard at sternum

• ± diastolic rumble b/c ↑ flow across valve

• Lat. displ. hyperdynamic PMI, obscured S1, widely split S2 (A2 early b/c ↓ LV afterload, P2 late if PHT); ± S3

• Carotid upstroke brisk (vs. diminished and delayed in AS)

![](https://i.imgur.com/s7r2Igm.jpg)

### Diagnostic studies (_NEJM_ 2005;352:875)

• ECG: may see LAE, LVH, ± atrial fibrillation

• CXR: dilated LA, dilated LV, ± pulmonary congestion

• **Echo:** MV anatomy (ie, etiol); MR severity: jet area, jet width at origin (vena contracta) or effective regurgitant orifice (ERO; predicts survival); LV fxn (EF should be _supranormal_ if compensated, ∴ EF <60% with sev. MR = LV dysfxn)

• TEE or cardiac MR if TTE not sufficiently informative

• Cardiac cath: prominent PCWP _c-v_ waves (not spec. for MR), LVgram for MR severity & EF

![](https://i.imgur.com/RU9Ixde.jpg)

\*1+ = LA clears with each beat; 2+ = LA does not clear, faintly opac. after several beats; 3+ = LA & LV opac. equal.

†For secondary MR, because ERO underestimated & likely progressive LV dysfxn, ERO ≥0.20 is severe

### 治療 (_Lancet_ 2016;387:1324; _Circ_ 2017;135:e1159; _JACC_ 2017;70:2421)

• **Acute severe MR:** consider ischemia & endocarditis as precipitants; IV afterload reduction (nitroprusside), relieve congestion (diuresis & NTG), ± inotropes (dobuta), IABP, avoid vasoconstrictors; _surgery_ usually needed b/c prognosis poor without (_JAMA_ 2013;310:609)

• **Chronic severe primary MR: surgery** (repair \[preferred if feasible\] vs. replacement) if **症狀 & EF >30%;  無症狀 & either EF 30–60% or LVESD ≥40 mm;** ?  無症狀, EF >60%, LVESD <40, but EF ↓ or LVESD ↑; MV repair reasonable if  無症狀 & either EF >60% + LVESD <40 mm or new AF or PHT; if AF, concomitant surgical ablation ↓ AF recurrence, ∅ ∆ stroke; consider for 症狀 cntl or if planning no anticoag (_NEJM_ 2015;372:1399)

• **_Secondary MR:_** if mod-sev MR (ideally ERO ≥0.40), EF 20–50%, 症狀 despite optimized GDMT, transcatheter MV repair with edge-to-edge clips appears to ↓ mortality and HF hosp (_NEJM_ 2018:379;2297 & 2307)

• For primary (degenerative) MR, surgery superior to percutaneous repair (_NEJM_ 2011;364:1395)

• Balloon-expandable bioprosthetic valve in severe MR with severe mitral annular calcification under study (_JACC_ 2018;71:1841)

• If 症狀 & EF<60% but not operative candidate: HF Rx (βB, ACEI, ± aldo antag); ↓ preload with diuretics, NTG (espec. if ischemic MR) for 症狀 relief ± ↓ ERO; maintain SR

• Asymptomatic: ∅ proven benefit of medical therapy; βB ↑ LV fxn (_JACC_ 2012;60:833)

MITRAL VALVE PROLAPSE (MVP)

### 定義 and Etiology

• Billowing of MV leaflet ≥2 mm above mitral annulus in parasternal long axis echo view

• Primary: sporadic or familial myxomatous proliferation of spongiosa of MV apparatus

• Secondary: trauma, endocarditis, congenital, CTD (eg, Marfan’s, OI, Ehlers-Danlos)

### 臨床表現 (usually asymptomatic)

• MR, endocarditis, emboli, arrhythmias (rarely SCD from VT from papillary muscle)

• High-pitched, midsystolic click (earlier with ↓ preload) ± mid-to-late systolic murmur

• No Rx _per se_ \[endocarditis Ppx not rec. (_Circ_ 2007;116:1736)\]; Rx MR as above

MITRAL STENOSIS (MS)

### Etiology (_Lancet_ 2012;379:953)

• **Rheumatic heart disease** (RHD): _fusion of commissures_ → “fish-mouth” valve

from autoimmune rxn to β strep infxn; seen largely in developing world today

• **Mitral annular calcification:** encroachment upon leaflets → fxnal MS; espec in ESRD

• Congenital, infectious endocarditis with large lesion, myxoma near MV, thrombus

• Valvulitis (eg, SLE, amyloid, carcinoid) or infiltration (eg, mucopolysaccharidoses)

### 臨床表現 (_Lancet_ 2009;374:1271)

• **Dyspnea and pulmonary edema** (if due to RHD, 症狀 usually begin in 30s)

precipitants: exercise, fever, anemia, volume overload (incl. pregnancy), tachycardia, AF

• **Atrial fibrillation:** onset often precipitates heart failure in 病人 with MS

• **Embolic events:** commonly cerebral, espec in AF or endocarditis

• Pulmonary: hemoptysis, frequent bronchitis (due to congestion), PHT, RV failure

• Ortner’s syndrome: hoarseness from LA compression of recurrent laryngeal nerve

![](https://i.imgur.com/lTHr8cl.jpg)

### Physical exam

• **Low-pitched mid-diastolic rumble at apex** with presystolic accentuation (if not in AF); best heard in L lat decubitus position during expiration, ↑ with exercise; severity proportional to _duration_ (not intensity) of murmur; loud S1

• **Opening snap** (high-pitched early diastolic sound at apex) from fused leaflet tips;

MVA proportional to S2–OS interval (tighter

valve → ↑ LA pressure → shorter interval)

• Loud S1 (unless MV calcified and immobile)

### Diagnostic studies

• ECG: **LAE** (“P mitrale”), ± AF, ± RVH

• CXR: **dilated LA** (flat L heart border, R double density, displaced L mainstem bronchus)

• **Echo:** estimate pressure gradient (∇), RVSP, valve area, valve echo score (0–16, based on leaflet mobility & thick, subvalvular thick., Ca++); exer. TTE (to assess ∆ RVSP and ∇) if 症狀 & severity of MS at rest discrepant; TEE to assess for LA thrombus before PMBC

• **Cardiac cath:** ∇, calculated MVA; LA tall _a_ wave & blunted _y_ descent; ↑ PA pressures

![](https://i.imgur.com/W8i1dTF.jpg)

### 治療 (_Circ_ 2014;129:e521; _Lancet_ 2016;387:1324)

• Medical: Na restriction, cautious diuresis, βB, AF control, 症狀-limited physical stress

• Antibiotic Ppx recommended if h/o RHD with valvular disease for 10 y or until age 40

• Anticoag: AF; prior embolism; LA clot; ? LA >55 mm or large LA with spont contrast

• Mechanical intervention indicated if **heart failure 症狀 with MVA** ≤**1.5;** reasonable if  無症狀 but very severe (MVA ≤1) and morphology favorable for PMBC; may consider PMBC if MVA >1.5 but hemodyn signif with exercise, or if  無症狀 but MVA ≤1.5 and new-onset AF

• **Percutaneous mitral balloon commissurotomy** (PMBC): preferred Rx if RHD; MVA doubles, ∇ ↓ by 50%; ≈ MVR _if_ valvuloplasty score <8, ∅ if mod-severe MR or LA clot

• Surgical (MV repair if possible, otherwise replacement): consider in 症狀 病人 with MVA ≤1.5

if PMBC unavailable/failed/contraindicated or valve morphology unsuitable

• Pregnancy: if NYHA class III/IV → PMBC, otherwise medical Rx with low-dose diuretic & βB

TRICUSPID REGURGITATION (_Circ_ 2014;129:2440; _Lancet_ 2016;388:2431)

• 1° etiol: rheumatic, CTD, XRT, IE, Ebstein’s, carcinoid, tumors, pacemaker leads

• Fxnl etiol (most common): RV and/or PHT (may be 2° to L-sided dis.), RV dilation ± MI

• Holosystolic murmur, 3rd/4th ICS, ↑ with insp (Carvallo’s sign); S3; prominent _cv_ wave in JVP

• Consider repair or replacement for 症狀 severe TR (eg, ERO ≥0.40 cm2); emerging transcatheter Rx under study: coaptation, caval implants, orthotopic valve (_JACC_ 2018;71:2935)

PROSTHETIC HEART VALVES

### Mechanical (60%)

• Bileaflet (eg, St. Jude Medical); tilting disk; caged-ball

• Very durable (20–30 y), but thrombogenic and ∴ require anticoagulation

consider if age <~50 y or if anticoagulation already indicated (_JACC_ 2010;55:2413)

### Bioprosthetic (40%)

• Bovine pericardial or porcine heterograft (eg, Carpentier-Edwards), homograft

• Less durable, but min. thrombogenic; consider if >~70 y, lifespan <20 y, or ∅ anticoag

• If 50–69 y, 2× reop but 1/2 bleeding or stroke vs. mech (_JAMA_ 2014;312:1323 & 2015;313:1435)

### Physical exam

• **Crisp sounds** ± soft murmur during forward flow (normal to have small ∇)

### Anticoagulation & antiplatelet therapy for surgical valves (_Circ_ 2017;135:e1159)

• _High-risk features:_ prior thromboembolism, AF, EF <30–35%, hypercoagulable

• **Warfarin (ØNOACs):** mech MVR or high-risk mech AVR: INR 3. Low-risk mech AVR or high-risk bio MVR/AVR: INR 2.5. Consider in bio MVR/AVR for 3–6 mo if low bleed risk.

• + **ASA** (≤100 mg): all prosth. valves unless hx GIB, uncontrolled HTN, erratic INR, or >80 y

• If thrombosis, ↑ intensity (eg, INR 2–3 → 2.5–3.5; 2.5–3.5 → 3.5–4.5; add ASA if not on)

• For TAVR, dual antiplatelet therapy (see TAVR section in “Aortic Stenosis”)

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p><b>Periprocedural “Bridging” of Anticoagulation in 病人 with Mechanical Valve(s)</b></p></td></tr><tr><td><p>AVR without risk factors</p></td><td><p>d/c warfarin 2–4 d before surg; restart 12–24 h after surg</p></td></tr><tr><td><p>MVR or AVR with risk factors</p></td><td><p>Preop: d/c warfarin, start UFH (preferred to LMWH) when INR &lt;2 4–6 h preop: d/c UFH; postop: restart UFH &amp; warfarin as soon as possible</p></td></tr></tbody></table>

_JACC_ 2017;70:253. Procedures include noncardiac surgery, invasive procedures, and major dental work.

### Correction of overanticoagulation (_Circ_ 2014;129:e521)

• Risk from major bleeding must be weighed against risk of valve thrombosis

• Not bleeding: if INR 5–10, withhold warfarin; if INR >10 also give vit K 1–2.5 mg PO

• Bleeding: FFP or PCC ± low-dose (1 mg) vit K IV

**Endocarditis prophylaxis:** for all prosthetic valves (see “Endocarditis”)

### Complications

• Structural failure (排除 endocarditis); mechanical valves: rare except for Bjork-Shiley; bioprosth: up to 30% rate within 10–15 y, mitral > aortic; consider TAVR (_JACC_ 2017; 69:2253)

• Paravalvular leak (排除 endocarditis); small _central_ jet of regurg is normal in mech. valves

• Obstruction from thrombosis (_JACC_ 2013;62:1731) or pannus: ✔ TTE, TEE, CTA, or fluoro significantly symptomatic _pannus_ ingrowth: remove with surgery

### thrombosis: surgery if L-sided valve & either severe 症狀 or large (≥1 cm or 0.8 cm2); otherwise UFH × days; if persists, consider lytic (eg, tPA 10 mg IVB → 90 mg over 2 hrs or 25 mg over 6 hrs repeating prn _JACC CV Imaging_ 2013;6:206), success in ~80%, but ~10% risk of death, stroke or major bleed; lytic reasonable for R-sided

• Infective endocarditis ± valvular abscess and conduction system dis. (see “Endocarditis”)

• Embolization (排除 endocarditis); risk highest 1st 90 d, ~1%/y with warfarin (vs. 2% with ASA, or 4% without meds); mech MVR 2× risk of embolic events vs. mech AVR (_Circ_ 1994;89:635)

• Bleeding (from anticoag), hemolysis (espec with caged-ball valves or paravalvular leak)
